These 2 pharmaceuticals look set to roll

Sigma Pharmaceutical Limited and Australian Pharmaceutical Industries Ltd are positioning themselves for sunnier days.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Reforms to the Pharmaceutical Benefits Scheme (PBS) have had a large impact on the financial performance of pharmaceuticals over the last couple of years, however conditions are now easing, offering opportunities in a demographically favourable sector.

Sigma Pharmaceutical Limited (ASX:SIP) is Australia's largest pharmacy driven wholesaler through the brands Amcal (including Amcal Max) and Guardian. The recent acquisition of Central Healthcare adds access to the large private and public hospital markets. Other initiatives by Sigma include the further development of exclusive and private labels, which are expected to cover over 300 products by the end of the 2014 calendar year; a heavy investment in data driven software allowing pharmacies to optimise store layouts and increase stock turns; plus the further automation of company owned distribution centres.

Following the 2013 collapse of Harrison Group (which operated 14 pharmacies and 6 medical centres) Sigma expensed $7.4m of bad debts in its latest (calendar) financial year. In common with other pharmaceutical wholesalers, generous terms (up to 60 days credit) are offered to pharmacies on stock. Sigma is carefully reducing term length with the aim of moving to a 45-day cycle. Although improved credit controls and reviews are now in place, retail pharmacies continue to do it tough presenting a continuing risk for wholesalers.

Sigma Pharmaceutical is well capitalised with no debt and $67 million in the bank. The acquisition of Central Healthcare will provide a positive impetus to profits in the current year and beyond. Growth in earnings over the next few years is estimated to be at least 6% per annum. A share price of 72c places Sigma on a 2014 (calendar year) price earnings ratio of 13.7. Sigma looks a solid buying opportunity with sustained growth prospects.

On face value Australian Pharmaceutical Industries Ltd (ASX:API) has a similar profile to Sigma, however there are stark differences:

1. API has higher exposure to direct retail – 22% of revenue versus Sigma at 4%.
2. Sigma's net margin is 2.4%; compared to API's 1.8%.
3. On three-year averages Sigma's bad debts total 0.1% of revenues; API's 0.8%.
4. Although Sigma has generous terms on stock, it doesn't directly put money into the retailer's business. API does through direct loans and an arrangement with Amex, where API assumes credit risk and the payment of all fees. In vulnerable times, this places API at much greater risk of bad debts/write-downs. Recently an asset impairment charge of $131m was signalled.

API's underlying earnings remain strong however and the current share price of 55c is likely to prove a reasonable buying point for this stock. Current debt to equity ratio is 20%.

Foolish takeaway

With pharmaceutical suppliers experiencing setbacks over the last few years it's a good time for investors to take a look at the opportunities available. With a high level of fixed costs in their businesses both Sigma and API have good leverage to any upturn in conditions. The effects of PBS reform are moderating as both companies make adjustments in their distribution platforms and sales mix. In my view Sigma is best positioned to benefit, although API has more upside to any further rises in consumer confidence.

Motley Fool contributor Peter Andersen owns shares in Sigma Pharmaceutical Limited

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »